{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:12:49Z","timestamp":1789665169573,"version":"4.0.1"},"reference-count":52,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005624","name":"Hannover Medical School","doi-asserted-by":"publisher","award":["HILF"],"award-info":[{"award-number":["HILF"]}],"id":[{"id":"10.13039\/501100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005624","name":"Hannover Medical School","doi-asserted-by":"publisher","award":["Young Academy"],"award-info":[{"award-number":["Young Academy"]}],"id":[{"id":"10.13039\/501100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB738, Cluster of Excellence REBIRTH, KFO286"],"award-info":[{"award-number":["SFB738, Cluster of Excellence REBIRTH, KFO286"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010570","name":"Nieders\u00e4chsisches Ministerium f\u00fcr Wissenschaft und Kultur","doi-asserted-by":"publisher","award":["REBIRTH"],"award-info":[{"award-number":["REBIRTH"]}],"id":[{"id":"10.13039\/501100010570","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Ovarian cancer is the most common cause of gynecological cancer-related death in the developed world. Disease recurrence and chemoresistance are major causes of poor survival rates in ovarian cancer patients. Ovarian cancer stem cells (CSCs) were shown to represent a source of tumor recurrence owing to the high resistance to chemotherapy and enhanced tumorigenicity. Chimeric antigen receptor (CAR)-based adoptive immunotherapy represents a promising strategy to reduce the risk for recurrent disease. In this study, we developed a codon-optimized third-generation CAR to specifically target CD44, a marker widely expressed on ovarian cancer cells and associated with CSC-like properties and intraperitoneal tumor spread. We equipped NK-92 cells with the anti-CD44 CAR (CD44NK) and an anti-CD19 control CAR (CD19NK) using lentiviral SIN vectors. Compared to CD19NK and untransduced NK-92 cells, CD44NK showed potent and specific cytotoxic activity against CD44-positive ovarian cancer cell lines (SKOV3 and OVCAR3) and primary ovarian cancer cells harvested from ascites. In contrast, CD44NK had less cytotoxic activity against CD44-negative A2780 cells. Specific activation of engineered NK cells was also demonstrated by interferon-\u03b3 (IFN\u03b3) secretion assays. Furthermore, CD44NK cells still demonstrated cytotoxic activity under cisplatin treatment. Most importantly, the simultaneous treatment with CD44NK and cisplatin showed higher anti-tumor activity than sequential treatment.<\/jats:p>","DOI":"10.3390\/biomedicines9101339","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T12:29:14Z","timestamp":1632832154000},"page":"1339","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0117-4366","authenticated-orcid":false,"given":"R\u00fcdiger","family":"Klapdor","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Institute for Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany"},{"name":"REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Comprehensive Cancer Center Niedersachsen, CCC Hannover, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Institute for Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Institute for Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany"},{"name":"REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Comprehensive Cancer Center Niedersachsen, CCC Hannover, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Institute for Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany"},{"name":"REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Comprehensive Cancer Center Niedersachsen, CCC Hannover, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-5833","authenticated-orcid":false,"given":"Jens","family":"Hachenberg","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Institute for Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Comprehensive Cancer Center Niedersachsen, CCC Hannover, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard","family":"B\u00fcning","sequence":"additional","affiliation":[{"name":"Institute for Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany"},{"name":"REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Comprehensive Cancer Center Niedersachsen, CCC Hannover, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9458-0282","authenticated-orcid":false,"given":"Thilo","family":"D\u00f6rk","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Comprehensive Cancer Center Niedersachsen, CCC Hannover, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-3531","authenticated-orcid":false,"given":"Peter","family":"Hillemanns","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Comprehensive Cancer Center Niedersachsen, CCC Hannover, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schambach","sequence":"additional","affiliation":[{"name":"Institute for Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany"},{"name":"REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Comprehensive Cancer Center Niedersachsen, CCC Hannover, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","article-title":"Carcinoma of the Ovary","volume":"95","author":"Heintz","year":"2006","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.immuni.2013.07.008","article-title":"The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures","volume":"39","author":"Galon","year":"2013","journal-title":"Immunity"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15621","DOI":"10.18632\/oncotarget.14919","article-title":"The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/mt.2011.256","article-title":"Redirected Antitumor Activity of Primary Human Lymphocytes Transduced with a Fully Human Anti-mesothelin Chimeric Receptor","volume":"20","author":"Lanitis","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1158\/1078-0432.CCR-10-0192","article-title":"Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen","volume":"16","author":"Chekmasova","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","article-title":"In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)","volume":"71","author":"Song","year":"2011","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1089\/hum.2017.168","article-title":"Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor\u2013Based Immunotherapy and Chemotherapy","volume":"28","author":"Klapdor","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.canlet.2012.10.023","article-title":"Ovarian cancer stem cells: Working towards the root of stemness","volume":"338","author":"Foster","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/jcb.23199","article-title":"Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile","volume":"112","author":"Latifi","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/stem.30","article-title":"Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44","volume":"27","author":"Takaishi","year":"2009","journal-title":"STEM CELLS"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1073\/pnas.0610117104","article-title":"Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma","volume":"104","author":"Prince","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","article-title":"Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ejca.2010.02.024","article-title":"CD44, a therapeutic target for metastasising tumours","volume":"46","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc3023","article-title":"CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule?","volume":"11","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0002-9440(10)65406-5","article-title":"CD44 and \u03b21 Integrin Mediate Ovarian Carcinoma Cell Adhesion to Peritoneal Mesothelial Cells","volume":"154","author":"Lessan","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_20","first-page":"3830","article-title":"Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H","volume":"53","author":"Kansas","year":"1993","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s12325-010-0010-0","article-title":"PF-03475952: A potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases","volume":"27","author":"Runnels","year":"2010","journal-title":"Adv. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00109-015-1327-6","article-title":"Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors","volume":"94","author":"Suerth","year":"2016","journal-title":"J. Mol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A Third-Generation Lentivirus Vector with a Conditional Packaging System","volume":"72","author":"Dull","year":"1998","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3109\/03008207.2015.1066780","article-title":"Cancer stem cells and the tumor microenvironment: Interplay in tumor heterogeneity","volume":"56","author":"Albini","year":"2015","journal-title":"Connect. Tissue Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1530\/REP-14-0234","article-title":"Epithelial ovarian cancer stem cells: Underlying complexity of a simple paradigm","volume":"149","author":"Garson","year":"2015","journal-title":"Reproduction"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/620523","article-title":"Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer","volume":"2011","author":"Steffensen","year":"2011","journal-title":"J. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9313","DOI":"10.18632\/oncotarget.3220","article-title":"Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer","volume":"6","author":"Gao","year":"2015","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ajpath.2011.11.015","article-title":"ALDH1-Bright Epithelial Ovarian Cancer Cells Are Associated with CD44 Expression, Drug Resistance, and Poor Clinical Outcome","volume":"180","author":"Wang","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/IGC.0b013e3182a1d023","article-title":"Effects and Mechanisms of Anti-CD44 Monoclonal Antibody A3D8 on Proliferation and Apoptosis of Sphere-Forming Cells with Stemness From Human Ovarian Cancer","volume":"23","author":"Du","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13841","DOI":"10.1073\/pnas.250484797","article-title":"A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells","volume":"97","author":"Dimitroff","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1083\/jcb.153.6.1277","article-title":"Cd44 Is a Major E-Selectin Ligand on Human Hematopoietic Progenitor Cells","volume":"153","author":"Dimitroff","year":"2001","journal-title":"J. Cell Biol."},{"key":"ref_32","first-page":"3985","article-title":"The role of hyaluronan in mesothelium-induced motility of ovarian carcinoma cells","volume":"23","author":"Carpenter","year":"2003","journal-title":"Anticancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1742-4658.2012.08589.x","article-title":"MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells","volume":"279","author":"Cheng","year":"2012","journal-title":"FEBS J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1541-7786.MCR-16-0191","article-title":"Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells","volume":"15","author":"Nakamura","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00280-010-1462-2","article-title":"Hyaluronic acid\u2013paclitaxel: Effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts","volume":"68","author":"Battaglia","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1158\/1078-0432.CCR-11-3250","article-title":"Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma","volume":"18","author":"Lee","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/bcr3674","article-title":"Construction and evaluation of a novel humanized HER2-specific chimeric receptor","volume":"16","author":"Sun","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1200\/JCO.2016.34.15_suppl.5511","article-title":"Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer","volume":"34","author":"Tanyi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"OncoImmunology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1089\/15258160152509145","article-title":"Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92","volume":"10","author":"Tonn","year":"2001","journal-title":"J. Hematother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14653240802301872","article-title":"Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial","volume":"10","author":"Arai","year":"2008","journal-title":"Cytotherapy"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/152581601750288975","article-title":"Factors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92","volume":"10","author":"Maki","year":"2001","journal-title":"J. Hematother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/hum.2018.247","article-title":"Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer\u2013Based \u201cOff-the-Shelf\u201d Acute Myeloid Leukemia Immunotherapies","volume":"30","author":"Kloess","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14653240310001523","article-title":"Ex vivo expansion of the highly cytotoxic human natural killer cell line NK-92 under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy","volume":"5","author":"Tarn","year":"2003","journal-title":"Cytotherapy"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ricciardelli, C., Ween, M.P., A Lokman, N., A Tan, I., E Pyragius, C., and Oehler, M.K. (2013). Chemotherapy-induced hyaluronan production: A novel chemoresistance mechanism in ovarian cancer. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-476"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cytogfr.2017.06.009","article-title":"Improving homing in T cell therapy","volume":"36","author":"Vignali","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","article-title":"Intracavitary \u2018T4 immunotherapy\u2019 of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells","volume":"393","author":"Klampatsa","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_52","first-page":"4539","article-title":"Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms","volume":"54","author":"Fox","year":"1994","journal-title":"Cancer Res."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:06:13Z","timestamp":1760166373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["biomedicines9101339"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9101339","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}